Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY

NCT06392841 is registered in ClinicalTrials.gov with Qian Qin as lead sponsor.

NCT NCT06392841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY
Lead sponsor
Qian Qin
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2025
Completion date
January 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 gene mutation, brca2 gene mutation, brip1 gene mutation, chek2 gene mutation, deleterious hrr gene mutation, fanca gene mutation, metastatic hormone-sensitive prostate cancer (mhspc), palb2 gene mutation, rad51b gene mutation, rad54l gene mutation